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clude all accommodations and ancillaries. Cost estimates,
adjusted for medical inflation and cost-to-charge ratios,
are reported in 1998 US$. RESULTS: From 1995 to
1998, the rate of hospital admissions for MA residents
with AIDS declined substantially. In 1995, 86% of the
3,162 AIDS patients were admitted at least once during
the year compared to 31% of the 5,636 patients in 1998.
The mean number of annual admissions per patient
dropped from 2 to 1.76 and the inpatient case fatality
rate fell from 6.7% to 4.6%. The mean LOS per AIDS
admission fell by 1.3 days; a greater decline than the 0.4
day average observed in MA over the same period. The
mean hospital stay cost decreased from $8,070 to
$7,538. These changes accounted for a $2,900 drop in
the mean annual hospitalization cost per AIDS patient
during that time. Discharge to sub-acute inpatient and
home health services fell by 8.6% in this period. All
changes reported are statistically significant (p  0.05).
CONCLUSIONS: The change in LOS is not the result of
post-discharge resource use shifting. The decrease in re-
source use and costs observed after the introduction of
HAART are consistent with an economically beneficial
impact of these agents.
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Although information exists in the form of projected
costs, limited data are available on the overall cost of ill-
ness resulting from varicella-zoster virus (VZV) infection.
VZV is usually a benign childhood illness, but reactiva-
tion of latent VZV can lead to serious complications.
OBJECTIVE: To assess via medical claims the costs asso-
ciated with VZV infection and its resultant complications
from the payers’ perspective. METHODS: We conducted
a retrospective database analysis of 73,869 managed care
members continuously enrolled throughout calendar year
1999. Records of members with a diagnosis code of ei-
ther primary varicella (ICD9-052) or herpes zoster (ICD-
053) were selected. Data was extracted and cost information
was tallied for all medical claims including inpatient hos-
pitalizations, primary care visits, specialist visits, emer-
gency department visits, and specialty procedures. Cost
data are reported in 1999 US dollars. RESULTS: In 1999,
a total of 119 patients were diagnosed with varicella
(52%) and herpes zoster (48%). The mean cost to the
payer was $496.77/patient. The average amount paid out
for members with varicella was $181.87. The average
cost per member with herpes zoster was $786.27. Sixty-
two (52%) VZV afflicted members were diagnosed with
varicella while 57 were diagnosed with herpes zoster. The
amount paid for members over age 19 (n  56) was
$640.30/patient. Of these patients, 14% were classified
with varicella infection, whereas 86% were classified as
having zoster. For members aged 19 (n  63), the mean
amount paid was $369.18/patient. In this group, 78%
were diagnosed with varicella infection, whereas 22%
were diagnosed with zoster. CONCLUSION: The above
costs document for the first time the true cost of VZV in-
fection from the payers’ perspective. Further efforts to
expand vaccination programs should take these costs into
consideration.
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OBJECTIVES: The aim of this analysis is to estimate the
economic impacts of oseltamivir treatment for influenza
in Japan. METHODS: A decision tree with endpoints of
occurrences of pneumonia was constructed to compare
two treatment strategies, oseltamivir treatment and con-
ventional treatment, for otherwise healthy adult (over 16)
patients with influenza like illness in Japan. Drug con-
sumption data (e.g., acetaminophen, antibiotics, and pal-
liative drugs for influenza like illness related symptoms)
were collected prospectively as well as work absenteeism
data as part of the Japanese placebo-controlled double-
blind multicenter study by oseltamivir that included 316
patients. Parameters used in the decision tree were mainly
derived from this study and combined with published
data. Sensitivity analyses were also performed to examine
the robustness of the results. RESULTS: Expected total
medical cost per patient was 14,100 yen and 14,412 yen
for oseltamivir treatment and conventional treatment, re-
spectively. Expected cost including production loss was
56,654 yen and 63,485 yen, for oseltamivir treatment
and conventional treatment, respectively. Based on the
results of basic analyses, the savings that could be ex-
pected in Japanese nationwide health care costs with
widespread use of oseltamivir ranged from 1.1 billion yen to
3.4 billion yen. CONCLUSION: This study suggested that
oseltamivir treatment for patients with flu-like symptoms
can be attractive from the societal perspective in Japan.
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Antibiotic resistance is of growing importance to the Ca-
nadian health care system due to the morbidity, mortal-
ity, and financial costs of certain pathogens for which
there are limited therapeutic options. Among the resistant
organisms, the incidence of methicillin-resistant Staphy-
lococcus species (MRSS) is rising and is posing an in-
creasing burden to health care systems. OBJECTIVE: To
characterize MRSS treatment patterns in patients with
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complicated and uncomplicated skin and soft tissue infec-
tions (SSTIs). METHODS: Five infectious disease experts
from across Canada were interviewed to understand their
current treatment practices. The interview responses were
used to design a chart review of 100 patients from three
acute-care facilities who were hospitalized for a SSTI
caused by MRSS. RESULTS: Approximately 60–100%
of SSTIs caused by MRSS are currently being treated with
vancomycin and, in the majority of these patients, the en-
tire treatment course (approximately 5–28 days) is re-
ceived via IV infusion. Other therapies included fusidic
acid and clindamycin. In all cases, IV therapy is initiated
in hospital, although approximately 20–60% of patients
are eventually able to be discharged to complete their IV
therapy with the assistance of home care. Additional data
collected in the survey include duration of intravenous
(IV) therapy, frequency of switch to oral therapy, and
length of oral therapy, hospital stay, and home IV care.
CONCLUSIONS: Despite the proven economic benefits
and wide acceptance of switch therapy, a large portion of
patients with SSTIs caused by MRSS are currently com-
pleting their entire treatment course via IV infusion. The
major reason cited is the lack of an effective oral thera-
peutic alternative. An oral antibiotic that is effective at
treating these types of infections, therefore, represents
cost-savings to hospitals by potentially reducing drug ad-
ministration costs, hospital length of stay due to early
discharge, and costs associated with home IV care.
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OBJECTIVE: To perform an economic analysis for the
treatment of Acute Exacerbations of Chronic Bronchitis
(AECB) comparing cefdinir 300mg twice a day for five
days to loracarbef 400mg twice a day for seven days.
METHODS: A randomized double-blind controlled trial
conducted in twenty-four US centers between October
1995 and June 1997 collected data whether patients be-
came cured or not after treatment with cefdinir or lora-
carbef as well as hospitalizations, clinic visits, and medi-
cations not related to the study medication. The final
analysis is reported from a third party payer perspective.
A total of 585 patients were randomized into two groups,
290 patients receiving cefdinir and 295 patients receiving
loracarbef. Symptoms for inclusion criteria were cough
and mucopurulent or purulent sputum production for
three consecutive months. History or clinical evidence of
other diseases and concomitant infections requiring sys-
temic antimicrobial therapy were among the exclusion
factors. RESULTS: The unadjusted cure rates for cefdinir
and loracarbef were very similar at 82.4% (239/290) and
80% (236/295) using ANOVA. Comparable efficacy was
further supported through a probit regression showing an
insignificantly higher cure rate for cefdinir of 10.3% (p 
0.4903). The unadjusted mean medical costs per case for
loracarbef were $345.03, 27.5 percent higher than cef-
dinir ($270.60). An ordinary least squares regression, in-
cluding patient characteristics as covariates, showed a
cost savings of $74.43 (p  0.001) associated with cef-
dinir. CONCLUSIONS: The key findings of the eco-
nomic analysis showed a significant cost savings by treat-
ing AECB with cefdinir 300mg twice a day for five days
as compared with loracarbef 400mg twice a day for seven
days. Furthermore, patients taking cefdinir had four less
doses, resulting in a higher state of compliance and con-
venience.
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OBJECTIVES: Urinary Tract Infection (UTI) was identi-
fied as the second most frequent complication at a large
hospital, occurring in 3% of patients admitted, and con-
tributing to $1.4 million in costs, during the study period
October 1998 to September 1999. This project was de-
signed to increase hospital awareness concerning UTI
complication, identify patient populations at-risk, and
evaluate treatments. METHODS: Risk adjustment devel-
oped at the University of Pennsylvania School of Medi-
cine was used to predict patients’ hospitalization compli-
cations. Complication rates were compared between
patients with and without UTI as a secondary diagnosis.
Laboratory data were analyzed to identify whether pa-
tients with a secondary diagnosis of UTI met CDC labo-
ratory diagnosis criteria. Differentiating patients by day
of onset identified potentially nosocomial UTI’s. Such pa-
tients were differentiated by DRG. Finally, the distribu-
tion of antibiotic treatments was determined. RESULTS:
While the predicted complication rate for patients with
UTI as a secondary diagnosis was 55.0%, their actual
rate was 79.2% (p  .001). 55% of such patients met
CDC laboratory diagnosis criteria; of these patients, 36%
were diagnosed 3 days from admission, i.e., had poten-
tially nosocomial UTI’s. Four DRG’s—Tracheostomy,
PTCA, CHF, and Hip & Knee Replacement—accounted
for 40% of all patients with UTI as a secondary diagno-
sis, but 80% of potentially nosocomial UTI patients.
Treatment for all UTI patients showed widespread Levo-
floxacin use, regardless of DRG. Of note, most UTI’s were
related to E. Coli, which can be treated more cost-effec-
tively with trimethoprim sulfamethoxazole. CONCLU-
SIONS: Based on this investigation, the hospital re-initi-
ated the National Nosocomial Infections Surveillance
System program for UTI’s, evaluated Levofloxacin use,
developed physician guidelines for UTI diagnosis and
treatment, and increased nursing education concerning
catheter care and maintenance protocols.
